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A polypeptide of 69 amino acids (PbCS 242–310) encompassing the C-terminal region of the
circumsporozoite protein of Plasmodium berghei (PbCS) was generated using solid-phase
peptide synthesis. The immunological and protective properties of peptide PbCS 242–310
were studied in BALB/c mice (H-2d). Two subcutaneous injections, in the presence of IFA at
the base of the tail, generated (i) high titers of anti-peptide antibodies which also recognized
the native P. berghei CS protein, (ii) cytolytic T cells specific for the Kd-restricted peptide
PbCS 245–253 and (iii) partial CD8+-dependent protection against sporozoite-induced
malaria. The same frequencies of peptide PbCS 245–253 specific CD8+ T cells were found
by IFN- + ELISPOT in the draining lymph nodes of animals immunized with the short optimal
CTL peptide 245–253 or with the polypeptide 242–310, indicating that the longer polypeptide
can be processed and presented in vivo in the context of MHC class I as efficiently as the short
CTL peptide. Interestingly, higher levels of IFN- + producing CD8+ T cells and protection were
observed when the four cysteine residues present in the C-terminal peptide were fully oxi-
dized. These findings underline the potential importance of the chemical nature of the C-
terminal fragment on the activation of the immune system and concomitant protection.
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1 Introduction
Malaria is a parasitic disease transmitted during the
blood meal of infected mosquitoes which inoculate spo-
rozoites into the mammalian host. Within minutes, spo-
rozoites invade hepatocytes and develop into merozo-
ites intracellularly by asexual schizogony. The merozo-
ites then invade cyclically red blood cells, thereby induc-
ing the appearance of the typical malaria symptoms. The
life-cycle is completed when gametocytes are ingested
during the blood meal of the mosquito vectors.
Protective immunity against malaria can be obtained
by immunizing mice and humans with irradiation-
attenuated sporozoites [1]. This immunity is the result of
the effect of neutralizing antibodies recognizing free spo-
rozoites in the blood stream and of CD4+ and CD8+ T
cells which prevent the development of the parasite
hepatic forms [2]. One aim in malaria vaccine research is
to mimick the protective immune response induced by
injection of irradiated sporozoites.
Murine malaria models have been extensively studied in
order to characterize the immune mechanisms required
to eliminate malaria hepatic stages. CD4+ and CD8+ T
lymphocytes were shown to be involved in the protection
mechanism at the liver stage. CD4+- dependent protec-
tion was acquired through injection of T cell clones
obtained after immunization with irradiated sporozoites
[3] or after injection of synthetic peptides covering epi-
topes in the N-flanking region of the CS of P. berghei [4].
Similarly, immunization with a linear synthetic peptide
from the sporozoite surface protein 2 (SSP2) of P. yoelii




CD8+-dependent protection was also reported using var-
ious immunization protocols. Protection induced by irra-
diated sporozoites was absent upon depletion of CD8+ T
cells [6] or in MHC class I knockout mice [7]. Further-
more, injection of CS protein-specific CTL clones [8, 9]
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Fig. 1. Evaluation of the cytotoxic activity in mice immunized
with peptide PbCS 245–253 or PbCS 242–310. BALB/c
mice were immunized twice s.c. with 20 ? g of the reduced
peptide PbCS 242–310 ( Æ ) or 4 ? g of PbCS 245–253 and
100 ? g of P30 ( | ) in IFA. Ten days after the boost, spleen
cells were isolated and cultured for 1 week in the presence
of PbCS 245–253 pulsed P815 cells. A group of mice immu-
nized with IFA alone was evaluated and served as negative
control ( , ). The results shown represent, for each E:T ratio,
the difference of the percentage of lysis between the peptide
PbCS 245–253 pulsed and unpulsed target cells.
conferred full protection against P. berghei. Studies
using Fas, Fas L, perforin and IFN- + receptor-deficient
mice indicated that protection is mediated by soluble
factors like IFN- + and TNF- § [10, 11].
Most of the studies undertaken so far have concentrated
on the use of peptides stimulating one or the other facet
of the immune system. In the design of a malaria vaccine
exploitation of multiple immune mechanisms against
parasite infection should be achieved and this might pro-
vide the desired level of protection against sporozoite
challenge.
We have already shown that long polypeptides contain-
ing N- or C-terminal parts of P. falciparum CS protein
induced neutralizing antibody responses in mice which
prevented P. falciparum sporozoite penetration in vitro
[12]. These peptides are also recognized by sera or PBL
of people living in endemic areas [13–15]. Moreover, long
polypeptides generate CD8+ T cell responses in vivo,
indicating that they can be adequately processed and
presented in the context of MHC class I molecules in vivo
[16, 17]. Here, we extend these studies to a model where
in vivo protection can be assessed and we confirm that
injection of polypeptide PbCS 242–310 induces a broad
stimulation of the immune system. Indeed, peptide
specific CD8+ T cells, antibodies specific for the native
protein, T helper cell proliferation and CD8+-dependent
protection against sporozoite-induced infection were
detected. Importantly, oxidation of the four cysteine resi-
dues present in the C-terminal fragment induced a
higher number of IFN- + producing lymphocytes and a
higher degree of protection against a parasite challenge.
2 Results
2.1 Immunological response to the fully reduced
PbCS 242–310 C-terminal peptide
BALB/c mice were immunized twice with peptide PbCS
242–310 in IFA. The presence of peptide-specific anti-
bodies was assessed 7–10 days after the second
injection. A high titer of peptide-specific antibodies
(1:300,000) was detected by ELISA and cross-reactivity
with the native CS protein (1:25,000) was demonstrated
by IFAT on P. berghei air-dried sporozoites. Recognition
of sporozoites was specific since it was inhibited by the
addition of competitor PbCS 242–310 peptide.
To assess the CTL response, spleen and LN immune
cells were restimulated in vitro with the well known CTL
epitope PbCS 245–253 [18], peptide PbCS 242–310 and
overlapping peptides B11-B17 covering the entire C-
terminal sequence. High levels of cytotoxicity were
detected in spleens and LN of immunized mice restimu-
lated with peptides 245–253 and 243–262, whereas
lower levels were induced by peptides 233–252 and
242–310 (data not shown). The cytotoxic activity was
similar to that obtained in mice immunized with the opti-
mal nonameric peptide PbCS 245–253 as determined by
CTL activity (Fig. 1) or by the number of IFN- + spot form-
ing cells (Fig. 2A). The Kd restriction of the CTL response
was confirmed using transfected L cells expressing Kd,
Dd or Ld MHC class I molecules (data not shown).
2.2 Immunization with PbCS 242–310 peptide in
IFA confers CD8+-dependent protection to
BALB/c mice exposed to parasite-bearing
mosquitoes
BALB/c mice immunized twice s.c. at the base of the tail
with 20 ? g PbCS 242–310 peptide in IFA were submitted
to a parasite challenge 7–10 days after the peptide
boost. An important level of specific protection was
obtained in the mice immunized with the PbCS 242–310
(Table 1, Experiment A). To characterize the mechanisms
of protection, T cell depletion was performed in vivo.
Clearly, the depletion of CD4+ T cells did not significantly
modify the observed protection. In contrast, depletion of
CD8+ T cells by isotype-matched CD8+-specific anti-
bodies prevented peptide-induced protection in vivo,
since a baseline level of protection was observed
(Table 1, Experiment A).
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Fig. 2. Determination of peptide PbCS 245–253 specific T
cells by IFN- + ELISPOT in LN cells. Mice were immunized
with various antigen preparations in IFA at the base of the tail
on day 0 and 3–4 weeks later: (A) peptide PbCS 242–310 or
peptides P30/PbCS 245–253; (B) reduced or oxidized PbCS
242–310. Inguinal and periaortic draining lymph nodes of
two mice per group were removed 10–20 days after the sec-
ond injection and cells obtained were pooled. The presence
of specific T cells was assessed directly by ELISPOT in the
presence of irradiated P815 pulsed or not with peptide
PbCS 245–253. Mice immunized with IFA only were used as
controls. Results are representative of two (A) and three (B)
experiments and are expressed as the difference of spots
obtained when cells were incubated with P815 cells pulsed
or not with the PbCS peptide 245–252.
Table 1. Protection studies in BALB/c mice using reduced or oxidized peptide PbCS 242–310a)
Experiment Immunization Treatment Protected/Exposed % Protection
A IFA 2/9 22
Reduced PbCS 242–310 Anti CD4 12/20 60
Reduced PbCS 242–310 Anti CD8 3/20 15
Reduced PbCS 242–310 12/20 60
B IFA 1/7 14
Oxidized PbCS 242–310 6/7 84
C IFA 2/8 25
Reduced PbCS 242–310 4/8 50
Oxidized PbCS 242–310 8/8 100
a) BALB/c mice were immunized twice with the indicated preparations. Anti-CD4 and -CD8 treatment was performed prior to
sporozoite injection as described in Sect. 4. Parasitemia was determined by Giemsa stained bloodsmears from day 5 to day
14. Mice were considered protected when no parasites were detected on day 14. The data shown in experiment A represent
the accumulated results of two individual experiments.
2.3 Immunological properties of the oxidized
PbCS 242–310 C-terminal peptide
Since the four cysteines present in the C-terminus of the
native CS protein are likely to be oxidized [19, 20], the
fully reduced C-terminal peptide was allowed to undergo
full oxidation by air-exposing it in an aqueous solution at
pH 8.0 for 10 days at room temperature. The immunolog-
ical properties of this preparation were then compared
with the fully reduced material in terms of antibody pro-
duction, T cell proliferation, CTL response and protective
capacity. While no substantial difference was obtained in
antibody titers and T cell proliferation (data not shown),
the number of IFN- + ELISPOT obtained with the oxidized
material in three different experiments was consistently
greater than that observed for the fully reduced peptide
(Fig. 2B). Experiments performed with purified LN and
spleen cells indicated that the response obtained in the
ELISPOT assay was confined to the CD8+ T cell popula-
tion (Fig. 3). Similarly, the degree of protection obtained
with the oxidized material was consistently higher than
that observed with the reduced molecule (Table 1, Exper-
iments B, C).
3 Discussion
Our present and previous results [16, 17] demonstrate
that long polypeptides are efficient immunogens. Here,
immunization with peptide PbCS 242–310 not only
generates a wide spectrum of immune responses but
also provides CD8+-dependent protection against
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Fig. 3. CD8+ T cell dependence of peptide PbCS 245–253
specific T cells in LN and spleen cells. Ex vivo PbCS
245–253 peptide-specific IFN- + ELISPOT assays were per-
formed 10 days after the second injection. BALB/c mice
were immunized two times s.c. at 3-week interval with 20 ? g
of oxidized (gray column) or reduced (black column) peptide
PbCS 242–310 in IFA. A group of mice immunized with adju-
vant alone is represented in the dashed column. Inguinal
and periaortic LN (panel A) and spleen (panel B) cells from
two individual mice were plated prior or after cell treatment
with anti-CD8a antibody: left columns, no treatment; center
columns, CD8+ T cells; right colums, CD8- cell population.
Results are expressed as the difference of spots obtained
when cells were incubated with P815 cells pulsed or not with
the PbCS peptide 245–252.
sporozoite-induced infection. In particular and unex-
pectedly, the oxidized material induces a higher number
of IFN-
+
-producing T cells and a better degree of protec-
tion against a sporozoite challenge. At this stage, we can
only speculate on the mechanism by which a better
IFN- + -producing CD8+ T cell response is elicited. From in
vitro studies, we have observed that the oxidized form is
more resistant to proteolytic degradation than the
reduced material. It is, therefore, possible that this prop-
erty might lead to a longer half-life of the peptide in vivo.
Alternatively, the oxidized material might interact more
efficiently with specific cell surface receptors specific for
the C-terminal part of the CS protein [19]. Either or both
mechanisms may provide for a more efficient antigen
presentation to specific CD8+ T cells.
We had previously reported that immunization of BALB/c
mice with a combination of tetanus toxin-derived helper
peptide P30 and CS-derived peptide PbCS 245–253
confers protection only when immune cells were trans-
ferred to naive recipients [21]. In the present study, the
injection of a reduced or oxidized long synthetic poly-
peptide covering the C-terminal region of the CS protein
conferred protection against Plasmodium berghei. While
the number of IFN-
+
–producing T cells detected was
higher in mice immunized with the oxidized polypeptide,
it has to be noted that the injection of the reduced form
induced a response which is similar to the response gen-
erated by the injection of the optimal nonameric peptide
PbCS 245–253. However, animals which have been
immunized with the reduced peptide were partially pro-
tected against a sporozoite challenge in a CD8+-
dependent manner. These results therefore suggest that
not only the amplitude of the CD8+-response is important
but also that the generation of a multi-facet immune
response can partially compensate a less important
CD8+ response.
It has been widely and independently demonstrated that
T helper cells and antibodies can independently provide
protection against malaria exoerythrocytic stages [3, 4,
22–24]. Here, we have shown that the peptide-specific
antibodies also have the capability to recognize the
native protein on P. berghei sporozoites and, therefore, it
is likely that they can neutralize sporozoites in vivo. This
might lead to a reduction in the number of infected hepa-
tocytes and to protection mediated by CD8+ T cells as a
result of the modification of the balance between the
hepatic stages and CD8+ T cells in favor of the latter. In
addition, injection of peptides PbCS 242–310 also
induced Th1 cell proliferation. In this study, however,
protection does not seem to be dependent on CD4+ T
cells. Here, CD4+ T cells may play a crucial role in the ini-
tiation of a peptide-specific immune response by provid-
ing help to specific CTL or B cells. However, it can not be
excluded that after anti CD4 antibody treatment the
remaining T cells (about 5%) may eliminate a certain pro-
portion of malaria liver stages by secretion of IFN- + or by
a yet unknown mechanism [10].
The data obtained in this animal study were the founda-
tion for using the oxidized CS terminal fragment of P. fal-
ciparum in an on-going Phase I human trial. The result so
far obtained indicate that antibody, T cell proliferation
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and CTL responses are also obtained in humans (manu-
script submitted).
Although the exact mechanisms leading to the genera-
tion of a more substantial CD8+ response in vivo remain
unclear, our studies show the importance of structural
parameters on the elicitation of the immune response
and suggest that the concertation of sub-optimal multi-
ple immune responses can lead to protection against a
sporozoite challenge.
4 Materials and methods
4.1 Peptide synthesis and analysis
All the peptides used in this study were chemically synthe-
sized using solid-phase F-moc chemistry, as described by
Merrifield and Atherton [25]. Chemicals and solvents used
for the synthesis were purchased from Bachem Feinchemi-
kalien (Bubendorf, Switzerland), Novabiochem (Läufelfin-
gen, Switzerland) and Fluka (Buchs, Switzerland). The 9-mer
peptide PbCS 245–253 corresponds to an identified CTL
epitope [8]. Polypeptide PbCS 242–310 covering the C-
terminal region of the circumsporozoite protein of Plasmo-
dium berghei ANKA strain [26] was obtained as previously
described in detail for the Plasmodium falciparum analogue
[12]. Briefly, the polypeptide was prepared on a p-
alkoxybenzylalcohol resin (Wang resin) with a degree of sub-
stitution of 0.4 mmol/g. A 10-fold excess of F-moc amino
acid derivatives and a 30 min coupling time were used. The
crude polypeptide was purified by a combination of size
exclusion chromatography (Sephadex G25, Pharmacia,
Sweden) and RP-HPLC (W-Porex 5 C4, 250 × 10 mm, Phe-
nomenex, Rancho Palos Verdes, USA) using a 10–50%
CH3CN gradient in 0.1% TFA/H2O in 40 min with a flow rate
of 3 ml/min. The 20-mer peptides B11-B17 which overlap
by 10 residues and encompass the sequence PbCS
233–312 were purified by size exclusion chromatography.
The degree of purity of all peptides was analyzed by RP-
HPLC (C18 analytical column). Amino acid composition of
purified peptides was determined according to Knecht [27]
and the molecular weight was confirmed by mass spectrom-
etry on an LDI 1700 Mass Monitor (Linear Scientific Inc.,
Reno, NV, USA) or a Voyager-DE (PerSeptive Byosystem,
Framingham, MA, USA).
4.2 Reduction and oxidization of PbCS 242–310
The reduced form of PbCS 242–310 was obtained by treat-
ing the HPLC purified polypeptide with a 100 molar excess
of DTT for 36 h at 37°C. After elimination of the DTT excess
by size exclusion chromatography, a portion of the material
was dissolved in 0.1 M CH3COONH4 pH 8.0 and left to air
oxidize for 10 days. The complete reduction or oxidization of
the peptide was confirmed both by the Ellman reaction and
by adding a 1000 molar excess of N-ethylmaleimide (NEM)
to an aliquot of the peptide solution. In the later case, after
incubation at 4°C for 1 h, no increase of the polypetide MW
was detected by mass spectrometry for the oxidized form
while the reduced form presented a MW increase corre-
sponding to the addition of four NEM molecules.
4.3 Immunization
Five- to six-weeks old female BALB/c mice were purchased
from Harlan (Zeist, NL). Mice were injected subcutaneously
at the base of the tail with 20 ? g reduced or oxidized poly-
peptide dissolved in PBS and emulsified in IFA. For the short
peptide PbCS 245–253, 4 ? g were injected in combination
with 100
?
g of the universal helper peptide P30 [21]. Animals
received a booster dose of immunogen after 3–4 weeks. Ten
to twenty days after the boost, mice were bled to assess the
production of specific antibodies. Subsequently, the animals
were either sacrificed for proliferation, CTL or ELISPOT
assays or exposed to sporozoite-bearing mosquitoes.
4.4 Parasite challenge
Plasmodium berghei (ANKA strain, clone 1, Dr. Walliker,
Edinburgh or Dr. P.H. Lambert, WHO, Geneva) sporozoites
were produced by cyclical transmission to laboratory-bred
Anopheles gambiae or A. stephensi mosquitoes. Mice were
anesthetized and exposed to infected mosquitoes. Mice
were individually exposed to a previously determined num-
ber of bites necessary to obtain a complete infection in naive
age-matched BALB/c mice. After parasite challenge, parasi-
temia was checked regularly from day 5 to day 14 by
Giemsa-stained bloodsmears. Mice were considered pro-
tected when no parasites were detected 14 days after the
challenge.
4.5 CTL induction by in vitro stimulation of
spleen cells
Spleen cells (40–60 millions) were cultured in 10 ml of
DMEM supplemented with 10 % FCS, 10 mM Hepes, 1%
Glutamine and 50 ? M g -mercaptoethanol; cells were cul-
tured in 25 cm2 tissue culture flasks (Falcon, Meylan, France)
in the presence of 1 ? M specific peptide. Cultures were har-
vested and tested for cytotoxicity 8–10 days after stimula-
tion.
4.6 Cytolytic assay
P815 mastocytoma cells were labeled with sodium chro-
mate (DuPont de Nemours) as described previously [18].
Labeled targets were co-incubated for 4 h with stimulated
spleen cells in V-bottom 96-well plates (Greiner, Nürtingen,
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Germany) at the indicated E:T ratios. Supernatants were
then collected for chromium-release measurement. The per-
cent specific lysis was calculated as: 100×(experimental-
spontaneous release)/(total-spontaneous release).
4.7 Magnetic cell sorting
Cells from periaortic and inguinal lymph nodes and from the
spleen were recovered from each individual mouse 10 days
after the second peptide immunization. The isolated cells
were washed two times with 10 ml of DMEM, 5% FCS and
1% Hepes. The spleen cells were further incubated at RT
with 5 ml of ACK lysing buffer (0.15 M NH4Cl, 1 mM KHCO3
and 0.1 mM EDTA, pH 7.2–7.4) per spleen for 5 min, in order
to lyse the red blood cells. The lysis was stopped by wash-
ing the spleen cells with 10 ml of DMEM, 5% FCS and 1%
Hepes. Lymph nodes and spleen cells were re-suspended in
PBS, 0.5% BSA and 2 mM EDTA and incubated at 4°C with
anti-mouse CD8a (Ly-2) antibody conjugated to super-
paramagnetic MicroBeads (Miltenyi Biotec, Bergisch Glad-
bach, Germany) for 20 min. The magnetic labeled cells were
washed and applied onto the separation columns (Miltenyi
Biotec). The negative selected cells were directly eluted from
the columns and the labeled cells were flushed out after
removing the column from the magnetic field. Cells were
washed, counted and plated for the ELISPOT assay.
4.8 T cell depletion in vivo
Hybridomas H35 (CD8-specific rat IgG2b) [28] and GK1.5
(CD4-specific rat IgG2b) [29] were a gift from Katherina Hug
(WHO-IRTC, Epalinges). Challenge was performed at day 0.
One milligram of CD4-specific antibodies was injected at
days –3, –2 and –1. Half milligram of CD8-specific anti-
bodies was injected at days –2 and +2. Depletion was
G
95% during the time required for the complete development
of P. berghei liver stages [30]. Depletion was verified by
FACS analysis of PBL or spleen cells using CD4-specific
FITC-labeled (Ref. 1300 024, Boehringer Mannheim, Ger-
many) and CD8-specific PE-labeled (Ref. 1271 237, Boeh-
ringer Mannheim, Germany) antibodies.
4.9 ELISPOT assay
Nitrocellulose ELISPOT (Millipore, Molsheim, France) plates
were coated overnight in a humid chamber at 4°C with a
PBS solution containing 100 ? g/ml of IFN- + -specific anti-
body OIE703B2. Saturation step was performed by adding
DMEM containing 10% FCS for 2 h at 37°C. Immune cells
isolated from the draining lymph nodes of immunized mice
were co-cultured for 24 h at 37°C in the plates with 100,000
irradiated P815 cells/well pulsed or not with the short pep-
tide PbCS 245–253. Cells were then removed and a second
IFN- + -specific biotinylated antibody (ANI) was added (1 ? g/
ml in PBS-1% BSA) for 2 h at 37°C. After washing,
streptavidin-alkaline phosphatase conjugate diluted in PBS-
5% FCS was added for 1 h at 37°C and the presence of
immune complexes revealed by the addition of BCIP/NBT
substrate.
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